Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853.

J Infect Dis. 2000 Apr;181(4):1486-90. Unique Identifier : AIDSLINE MED/20227780
MacArthur RD; Lederman MM; Benson CA; Chernoff MC; MacGregor RR; Spritzler J; Mahon LF; Yen-Lieberman B; Purvis S; Wayne State University, Department of Medicine, Division of; Infectious Diseases, Detroit, MI 48201, USA.; macarthur@intmed.wayne.edu

Abstract: Human immunodeficiency virus (HIV) type 1-infected persons with newly diagnosed Mycobacterium avium complex (MAC) bacteremia were enrolled in an 8-week study to determine whether treatment of MAC infection is associated with decreases in plasma tumor necrosis factor (TNF)-alpha levels. Blood specimens were obtained for quantitative MAC cultures and to determine plasma levels of HIV RNA, TNF-alpha, and other proinflammatory cytokines. MAC levels decreased by 1.75 log at week 4 (P=.008) and by 2.48 log at week 8 (P=.001). Plasma TNF-alpha decreased by 0.15 log at week 4 (P=.042) and by 0. 40 log at week 8 (P=.027). Plasma interleukin (IL)-6 decreased by 0. 56 log at week 8 (P=.039). There were nonsignificant trends (P<.10) for plasma levels of IL-1beta and HIV RNA to decrease at week 8. Nonsignificant decreases in plasma levels of TNF-alpha, IL-1beta, IL-6, and HIV RNA were also seen in those individuals who remained on stable antiretroviral therapy throughout the 8 weeks of the study.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adult Antibiotics, Macrolide/THERAPEUTIC USE Antitubercular Agents/THERAPEUTIC USE AIDS-Related Opportunistic Infections/*BLOOD/*DRUG THERAPY Clarithromycin/THERAPEUTIC USE Cytokines/*BLOOD Ethambutol/THERAPEUTIC USE Human Interleukin-1/BLOOD Interleukin-6/BLOOD Mycobacterium avium-intracellulare Infection/*BLOOD/*DRUG THERAPY Pilot Projects Rifabutin/THERAPEUTIC USE RNA, Viral/ANALYSIS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Tumor Necrosis Factor/METABOLISM Viral Load

000830
A0080944

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .